Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in Q3.

Becton Dickinson (BDX) Earnings Surpass Estimates in Q3

FRANKLIN LAKES, N.J., Aug. 6, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.855 billion for the third fiscal quarter ended June 30, 2020.

BD Announces Results For 2020 Third Fiscal Quarter; Provides Fiscal 2020 Guidance

Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Becton, Dickinson (BDX) Might Surprise This Earnings Season

Becton, Dickinson's (BDX) fiscal third-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.

What's in Store for Becton, Dickinson's (BDX) Q3 Earnings?

The company obtained Emergency Use Authorization for its coronavirus test in early July.

Becton, Dickinson Receiving $24 Million Federal Investment to Ramp Up Coronavirus Test Kit Manufacturing

FRANKLIN LAKES, N.J., July 30, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $24 million investment from the U.S.

BD Announces $24 Million U.S. Government Investment to Support Scale Up of U.S.

Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Becton Dickinson (BDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

FRANKLIN LAKES, N.J., July 27, 2020 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 per common share, payable on September 30, 2020 to holders of record on September 9, 2020.

BD Board Declares Dividends

The company says most of these will be filled by the end of this year.

Becton, Dickinson Reports Coronavirus-Related Surge in Injection Equipment Orders From U.S. and Canada

FRANKLIN LAKES, N.J., July 22, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it received approval for a pre-market approval (PMA) supplement from the U.S.

BD receives FDA Approval for HPV Test with Extended Genotyping Capabilities

Thermo Fisher Scientific

When the economy struggles, these two pharma companies take it in stride because they know the rest of the industry depends on them for critical products.

2 Top Pharma Stocks to Buy in a Recession

QuidelOrtho Corp

Distribution of rapid point-of-care diagnostic instruments from Quidel and Becton, Dickinson will begin next week.

Federal Government to Send Millions of COVID-19 Tests to Nursing Homes

Becton Dickinson and Co. BDX, 1.39% said Wednesday that the U.S. government plans to buy 750,000 of the company's COVID-19 antigen diagnostic tests.

BD to sell 750,000 coronavirus tests to U.S. government

Becton, Dickinson Inc (NYSE:BDX) was trading 1.6% higher from the previous closing price.

Insider Sells Becton, Dickinson's Stock

Becton, Dickinson (BDX) forms a strategic public-private partnership with BARDA to help the U.S. government in its efforts to fight the COVID-19 pandemic and future pandemics.

BD Collaborates With BARDA to Combat Coronavirus Crisis

Boston Scientific

Medtronic

High demand for a single product can't sustain an industry.

Why These Top Medical Device Stocks Have Fallen by Double Digits So Far in 2020

Becton, Dickinson (BDX) receives EUA from the FDA for a rapid, point-of-care, antigen test to detect SARS-CoV-2 in 15 minutes.

BD Receives EUA for New Antigen Test to Combat COVID-19

By developing fully sterile PurPrep, BD (BDX) is offering health care experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.

BD Unveils BD PurPrep Patient Preoperative Skin Preparation

Becton Dickinson & Co. said Wednesday that it will receive $42 million from the U.S. government to build out manufacturing capacity for vaccine injection devices, to be used during the coronavirus pandemic.

BD to get $42 million to manufacture vaccine injection devices

FRANKLIN LAKES, N.J., July 8, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced Research and Development Authority (BARDA),...

BD Partners with U.S. Government on $70 Million Manufacturing Infrastructure Project for Mass Vaccination Campaigns

American Airlines

Delta Air Lines

JetBlue Airways

Southwest Airlines

United Continental Hlds

Walmart

Paychex

Also, Paychex earnings disappoint, and Becton, Dickinson was granted authorization for a 15-minute COVID-19 test.

S&P 500 Falls 34 Points: Airline Stocks Fall on Federal Aid Deal; Walmart Starting Prime Competitor but Amazon Stock Stays Above $3,000

Shares of Becton Dickinson & Co.  were down 0.7% in premarket trading on Tuesday, the day after the Food and Drug Administration issued an alert about an increased risk of false-positive results for one of BD's COVID-19 diagnostic tests.

FDA alerts health care providers about false positives for one of BD's COVID-19 tests

FRANKLIN LAKES, N.J., July 7, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the availability of BD PurPrep™ patient preoperative skin preparation with sterile solution, the first and only fully sterile...

BD Launches First and Only Fully Sterile Povidone-Iodine and Isopropyl Alcohol Skin Preparation

The test is based on the company's BD Veritor Plus System, a handheld diagnostic device.

FDA Approves Becton Dickinson Portable 15-Minute Coronavirus Test

Becton Dickinson gained U.S. authorization for its third coronavirus test on Monday, sending BDX stock flying in early action.

News for Becton, Dickinson and Co. Stock (BDX)